In This Article:
Axogen (NASDAQ:AXGN) First Quarter 2025 Results
Key Financial Results
-
Revenue: US$48.6m (up 17% from 1Q 2024).
-
Net loss: US$3.83m (loss narrowed by 42% from 1Q 2024).
-
US$0.085 loss per share (improved from US$0.15 loss in 1Q 2024).
We check all companies for important risks. See what we found for Axogen in our free report.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Axogen EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 8.1%.
Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US.
Performance of the American Medical Equipment industry.
The company's shares are down 32% from a week ago.
Valuation
Our analysis of these results suggests Axogen may be undervalued based on 6 important criteria we look at. To explore our complete evaluation click here and get an understanding of what analysts are thinking about the company's future.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.